Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
Voehringer DW, Hirschberg DL, Xiao J, Lu Q, Roederer M, Lock CB, Herzenberg LA and Steinman L
The companies that recognize this reality and innovate accordingly will capture the greatest share of what promises to be one of the largest therapeutic markets in pharmaceutical history
It harnesses the potency of its key ingredients to deliver a refreshed, revitalized, and enhanced skin from within
Yet striking first does not always presage market dominance
Expected appearance: Clear solution with a very pale blue tint from the GHK-Cu copper(II) complex